Clinical trial
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced…
NCT00005591 · University of Alabama at Birmingham, Other · Withdrawn
Key facts
| NCT number | NCT00005591 |
|---|---|
| Title | Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas |
| Official title | Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody C225 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, gemcitabine hydrochloride |
| Enrollment | 0 |
| Start date | Oct 1, 1999 |
| Primary completion | Apr 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | Aug 9, 2004 |
| Last update posted | Dec 13, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: